deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03487445

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction

Sponsor: Viatris Innovation GmbH

Conditions Acute Myocardial Infarction
Interventions Selatogrel 16 mg Selatogrel 8 mg
Updated 15 times since 2018 Last updated: Jun 30, 2025 Started: Jul 10, 2018 Primary completion: Nov 10, 2018 Completion: Nov 10, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03487445, this PHASE2 trial focuses on Acute Myocardial Infarction and remains completed. Sponsored by Viatris Innovation GmbH, it has been updated 15 times since 2018, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 13 months · monthly snapshot

Change History

15 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Nov 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Sep 2021 — Nov 2021 [monthly]

    Completed PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  4. Sep 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2019 — Sep 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jun 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE2

  10. May 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Viatris Innovation GmbH
Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations